404 related articles for article (PubMed ID: 25899749)
1. Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
Na SY; Mracsko E; van Ryn J; Veltkamp R
Ann Neurol; 2015 Jul; 78(1):137-41. PubMed ID: 25899749
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
Zhou W; Schwarting S; Illanes S; Liesz A; Middelhoff M; Zorn M; Bendszus M; Heiland S; van Ryn J; Veltkamp R
Stroke; 2011 Dec; 42(12):3594-9. PubMed ID: 21998060
[TBL] [Abstract][Full Text] [Related]
3. Does dabigatran increase the risk of delayed hematoma expansion in a rat model of collagenase-induced intracerebral hemorrhage?
Tanoue S; Inamasu J; Yamada M; Toyama H; Hirose Y
J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):374-80. PubMed ID: 25444028
[TBL] [Abstract][Full Text] [Related]
4. Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography.
Won SY; Schlunk F; Dinkel J; Karatas H; Leung W; Hayakawa K; Lauer A; Steinmetz H; Lo EH; Foerch C; Gupta R
Stroke; 2013 Oct; 44(10):2883-90. PubMed ID: 23920016
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.
Sun L; Zhou W; Ploen R; Zorn M; Veltkamp R
Thromb Haemost; 2013 Jul; 110(1):153-61. PubMed ID: 23615682
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
8. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
Simonsen CZ; Steiner T; Tietze A; Damgaard D
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e133-4. PubMed ID: 24103671
[TBL] [Abstract][Full Text] [Related]
11. Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
Schaefer JH; Leung W; Wu L; Van Cott EM; Lok J; Whalen M; van Leyen K; Lauer A; van Ryn J; Lo EH; Foerch C
J Cereb Blood Flow Metab; 2014 May; 34(5):870-5. PubMed ID: 24549187
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab: First Global Approval.
Burness CB
Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
[TBL] [Abstract][Full Text] [Related]
13. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report.
Faust AC; Peterson EJ
J Emerg Med; 2014 Apr; 46(4):525-9. PubMed ID: 24508114
[TBL] [Abstract][Full Text] [Related]
14. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
Bouchard J; Ghannoum M; Bernier-Jean A; Williamson D; Kershaw G; Weatherburn C; Eris JM; Tran H; Patel JP; Roberts DM
Clin Toxicol (Phila); 2015 Mar; 53(3):156-63. PubMed ID: 25661675
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
17. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of hematoma expansion in murine warfarin-associated intracerebral hemorrhage.
Illanes S; Zhou W; Heiland S; Markus Z; Veltkamp R
Brain Res; 2010 Mar; 1320():135-42. PubMed ID: 20085756
[TBL] [Abstract][Full Text] [Related]
19. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Tireli D; He J; Nordling MM; Wienecke T
J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.
Lauer A; Cianchetti FA; Van Cott EM; Schlunk F; Schulz E; Pfeilschifter W; Steinmetz H; Schaffer CB; Lo EH; Foerch C
Circulation; 2011 Oct; 124(15):1654-62. PubMed ID: 21911784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
